METHODS FOR TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN
Application
US20260078198A1
Kind: A1
Mar 19, 2026
Inventors
Iris Tranthuyngan TO, Jue WANG, Carol Elaine O'HEAR, Yasuhiro OKI, Song Ha PHAM
Abstract
The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorders, such as a non-Hodgkin's lymphoma (NHL); e.g., an aggressive NHL or a relapsed and/or refractory NHL). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
CPC Classifications
C07K 16/2887
A61K 31/135
A61K 31/167
A61K 31/555
A61K 31/573
A61K 31/7068
A61K 47/68031
A61K 47/6849
A61K 47/6867
A61P 35/00
C07K 16/2809
C07K 16/2866
A61K 2039/507
A61K 2039/54
A61K 2039/545
Filing Date
2025-08-28
Application No.
19312481